マーケットレポート詳細
チロシンキナーゼ阻害薬：世界市場2028年予測
Tyrosine Kinase Inhibitors: Global Market Outlook
- 出版元：BCC Research
出版元について - 発行年：2023年11月
- 定価 ：Single User License(1名様ライセンス)US$3,500 (米国ドル) /2 to 5 Users License(5名様)$4,200 /Site License $5,040 / Enterprise License $6,048
- ご予算に応じた各種ご提案も承ります。詳細はお問い合わせください。
- ご請求は円換算（お見積り日TTSレート）となります。
- 納品形態：PDF by Email
- 当調査レポートは英文75ページになります。
- 商品コード：BCC475
お問い合わせ、お見積りのリクエストは下のボタンをクリックしてご入力ください。
【レポート紹介】
チロシンキナーゼ阻害薬の世界市場規模は2022年で447億ドル、2028年に651億ドル、市場の平均年成長率は6.5%になると予測されています。
当レポートでは、チロシンキナーゼ阻害薬の市場/技術的背景、各種セグメント別市場分析(タイプ別、用途別、国地域別)、市場概要、ESGの展開、主要企業プロフィールなどを盛り込み、概略以下の構成でお届けいたします。
【レポート構成概要】
◆イントロダクション
・調査目的
・調査対象
・調査手法
◆サマリーと調査ハイライト
◆市場概要
・キナーゼ阻害薬
・キナーゼ阻害剤の種類
・チロシンキナーゼ阻害剤
・規制シナリオ
・市場ダイナミクス（促進要因、障壁、機会）
◆チロシンキナーゼ阻害薬市場：タイプ別
・受容体型チロシンキナーゼ阻害剤
・非受容体型チロシンキナーゼ阻害剤
※市場予測データ掲載-2028年
◆チロシンキナーゼ阻害薬市場：用途別
・肺癌
・慢性骨髄性白血病（CML）
・その他用途
※市場予測データ掲載-2028年
◆市場：主要国地域別市場予測
・北米
・欧州
・アジア太平洋
・その他地域
※地域別に主要国別の細分化データ掲載
※地域別に全セグメントの細分化データ掲載、詳細は目次参照
◆ESGの展開
・チロシンキナーゼ阻害薬メーカーの持続可能性
・製薬業界におけるエンドユーザーの持続可能性
・ケーススタディ
・BCC Researchの観点
◆産業構造
・上位企業ランキング
・パイプライン分析
・特許分析
・最新動向
◆チロシンキナーゼ阻害薬市場の主要企業プロフィール
・ASTRAZENECA
・BAYER AG
・BOEHRINGER INGELHEIM INTERNATIONAL GMBH
・BRISTOL-MYERS SQUIBB CO.
・エーザイ株式会社
・F. HOFFMANN-LA ROCHE LTD.
・JOHNSON & JOHNSON SERVICES INC.
・NOVARTIS AG
・PFIZER INC.
【レポート詳細目次、データ項目一覧は当ページ下を参照ください】
Table of Contents (英文詳細目次）
Chapter 1 Introduction
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Methodology
Information Sources
Geographic Breakdown
Segmentation Breakdown
Chapter 2 Summary and Highlights
Market Outlook
Market Summary
Chapter 3 Market Overview
Kinase Inhibitors
Types of Kinase Inhibitors
Tyrosine Kinase Inhibitors
Regulatory Scenario
Market Dynamics
Drivers
Restraints
Opportunities
Chapter 4 Market Breakdown by Type and Application
Market for Tyrosine Kinase Inhibitors, by Type
Receptor Tyrosine Kinase Inhibitors
Non-receptor Tyrosine Kinase Inhibitors
Market for Tyrosine Kinase Inhibitors, by Application
Lung Cancer
Chronic Myelogenous Leukemia (CML)
Others
Chapter 5 Market Breakdown by Region
Global Market for Tyrosine Kinase Inhibitors, by Region
North America
Europe
Asia-Pacific
Rest of the World
Chapter 6 ESG Development
Introduction to ESG
The Sustainability of Tyrosine Kinase Inhibitor Manufacturers in the Industry
Pharma End User Sustainability in the Industry
Case Study
BCC Research Viewpoint
Chapter 7 Industry Structure
Ranking of Top Companies
Pipeline Analysis
Patent Analysis
Emerging Trends
Chapter 8 Company Profiles
ASTRAZENECA
BAYER AG
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
BRISTOL-MYERS SQUIBB CO.
EISAI CO. LTD.
F. HOFFMANN-LA ROCHE LTD.
JOHNSON & JOHNSON SERVICES INC.
NOVARTIS AG
PFIZER INC.
List of Tables
Summary Table : Global Market for Tyrosine Kinase Inhibitors, by Region, Through 2028
Table 1 : Characteristics of ATP-competitive and Non-ATP Competitive Inhibitors
Table 2 : Types of Receptor Tyrosine Kinase Inhibitors
Table 3 : Types of Non-receptor Tyrosine Kinase Inhibitors
Table 4 : FDA-approved Kinase Inhibitors, 2001-2021
Table 5 : FDA-approved Tyrosine Kinase Inhibitors and Their Drug Targets
Table 6 : EMA-approved Kinase Inhibitors, 2001-2020
Table 7 : Patent Expiration Dates of Tyrosine Kinase Inhibitors
Table 8 : Global Market for Tyrosine Kinase Inhibitors, by Type, Through 2028
Table 9 : Global Market for Receptor Tyrosine Kinase Inhibitors, by Region, Through 2028
Table 10 : Global Market for Non-receptor Tyrosine Kinase Inhibitors, by Region, Through 2028
Table 11 : Approved Tyrosine Kinase Inhibitors and Their Targets and Indications
Table 12 : Global Market for Tyrosine Kinase Inhibitors, by Application, Through 2028
Table 13 : Global Market for Tyrosine Kinase Inhibitors Used to Treat Lung Cancer, by Region, Through 2028
Table 14 : Global Market for Tyrosine Kinase Inhibitors Used to Treat CML, by Region, Through 2028
Table 15 : Global Market for Tyrosine Kinase Inhibitors Used in Other Applications, by Region, Through 2028
Table 16 : Global Market for Tyrosine Kinase Inhibitors, by Region, Through 2028
Table 17 : North American Market for Tyrosine Kinase Inhibitors, by Type, Through 2028
Table 18 : North American Market for Tyrosine Kinase Inhibitors, by Application, Through 2028
Table 19 : North American Market for Tyrosine Kinase Inhibitors, by Country, Through 2028
Table 20 : European Market for Tyrosine Kinase Inhibitors, by Type, Through 2028
Table 21 : European Market for Tyrosine Kinase Inhibitors, by Application, Through 2028
Table 22 : European Market for Tyrosine Kinase Inhibitors, by Country, Through 2028
Table 23 : Asia-Pacific Market for Tyrosine Kinase Inhibitors, by Type, Through 2028
Table 24 : Asia-Pacific Market for Tyrosine Kinase Inhibitors, by Application, Through 2028
Table 25 : Asia-Pacific Market for Tyrosine Kinase Inhibitors, by Country, Through 2028
Table 26 : Rest of the World Market for Tyrosine Kinase Inhibitors, by Type, Through 2028
Table 27 : Rest of the World Market for Tyrosine Kinase Inhibitors, by Application, Through 2028
Table 28 : Key Focus Areas in ESG Metrics
Table 29 : ESG Rankings for Major Pharma Companies Manufacturing TKIs, 2023
Table 30 : Revenue from Sales of Selected Tyrosine Kinase Inhibitors, 2020-2022
Table 31 : Ongoing Clinical Trials of Various Tyrosine Kinase Inhibitors
Table 32 : Patents Filed on Tyrosine Kinase Inhibitors, 2018-2022
Table 33 : AstraZeneca: Tyrosine Kinase Inhibitor Drug Product Portfolio
Table 34 : Bayer AG: Tyrosine Kinase Inhibitor Drug Product Portfolio
Table 35 : Boehringer Ingelheim International GmbH: Tyrosine Kinase Inhibitor Drug Product Portfolio
Table 36 : Bristol-Myers Squibb Co.: Tyrosine Kinase Inhibitor Drug Product Portfolio
Table 37 : Eisai Co. Ltd.: Tyrosine Kinase Inhibitor Drug Product Portfolio
Table 38 : F. Hoffmann-La Roche Ltd.: Tyrosine Kinase Inhibitor Drug Product Portfolio
Table 39 : Johnson & Johnson Services Inc.: Tyrosine Kinase Inhibitor Drug Product Portfolio
Table 40 : Novartis AG: Tyrosine Kinase Inhibitor Drug Product Portfolio
Table 41 : Pfizer Inc.: Tyrosine Kinase Inhibitor Drug Product Portfolio
List of Figures
Summary Figure A : Global Market Shares of Tyrosine Kinase Inhibitors, by Region, 2022
Summary Figure B : Growth Rate of North America, Europe, and Asia-Pacific Markets for Tyrosine Kinase Inhibitors, 2023-2028
Figure 1 : Share of Estimated Number of New Cancer Cases Among Women, by Cancer Type, 2020
Figure 2 : Share of Estimated Number of New Cancer Cases Among Men, by Cancer Type, 2020
Figure 3 : National Cancer Institute Research Funding, 2012-2019
Figure 4 : Global Market Shares of Tyrosine Kinase Inhibitors, by Type, 2022
Figure 5 : Global Market Shares of Tyrosine Kinase Inhibitors, by Application, 2022
Figure 6 : Global Mrket for Tyrosine Kinase Inhibitors, by Region
Figure 7 : Global Market Shares of Tyrosine Kinase Inhibitors, by Region, 2022
Figure 8 : Global Market Shares of Tyrosine Kinase Inhibitors by Region, 2028
Figure 9 : How a Strong ESG Proposition Benefits Businesses
Figure 10 : The 10 Business Sustainability Trends Identified for 2022
Figure 11 : ESG Adoption Level Across All Industries, 2021 and 2022
Figure 12 : Key Sustainable Practices Being Implemented in Research Laboratories
Figure 13 : ESG Commitments of Pfizer
Figure 14 : Company Shares of the Market for Tyrosine Kinase Inhibitors, 2022
Figure 15 : Distribution Share of Clinical Trial Phases of Various Tyrosine Kinase Inhibitors
Figure 16 : Number of Patents Filed, Granted and Published, 2018-March 2023